UBS Asset Management Americas Inc. reduced its position in Shire PLC (NASDAQ:SHPG) by 54.2% during the first quarter, Holdings Channel reports. The fund owned 162,793 shares of the biopharmaceutical company’s stock after selling 192,712 shares during the period. UBS Asset Management Americas Inc. owned about 0.05% of Shire PLC worth $28,363,000 as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in SHPG. Dumont & Blake Investment Advisors LLC increased its stake in shares of Shire PLC by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 2,594 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 7 shares during the last quarter. Bienville Capital Management LLC increased its stake in shares of Shire PLC by 0.4% in the fourth quarter. Bienville Capital Management LLC now owns 2,453 shares of the biopharmaceutical company’s stock worth $418,000 after buying an additional 9 shares during the last quarter. Macquarie Group Ltd. increased its stake in shares of Shire PLC by 2.2% in the fourth quarter. Macquarie Group Ltd. now owns 1,417 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 31 shares during the last quarter. North Star Investment Management Corp. increased its stake in shares of Shire PLC by 8.5% in the first quarter. North Star Investment Management Corp. now owns 756 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 59 shares during the last quarter. Finally, Osborne Partners Capital Management LLC increased its stake in shares of Shire PLC by 0.3% in the first quarter. Osborne Partners Capital Management LLC now owns 18,988 shares of the biopharmaceutical company’s stock worth $3,308,000 after buying an additional 60 shares during the last quarter. 21.28% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC (SHPG) opened at 164.72 on Friday. The firm’s 50-day moving average is $177.23 and its 200-day moving average is $174.21. The company has a market capitalization of $49.06 billion, a PE ratio of 168.94 and a beta of 1.57. Shire PLC has a 12 month low of $161.09 and a 12 month high of $209.22.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The firm’s revenue was up 109.0% on a year-over-year basis. During the same period last year, the company earned $2.12 earnings per share. Equities analysts anticipate that Shire PLC will post $14.90 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.wkrb13.com/markets/2229711/shire-plc-shpg-stake-decreased-by-ubs-asset-management-americas-inc.html.
A number of brokerages have recently issued reports on SHPG. Jefferies Group LLC set a $239.00 price target on shares of Shire PLC and gave the stock a “buy” rating in a report on Saturday, March 18th. Cowen and Company reissued an “outperform” rating and issued a $325.00 price target on shares of Shire PLC in a report on Wednesday, May 31st. Cantor Fitzgerald began coverage on shares of Shire PLC in a report on Friday. They issued an “overweight” rating and a $222.00 price target on the stock. BidaskClub downgraded shares of Shire PLC from a “sell” rating to a “strong sell” rating in a report on Friday. Finally, ValuEngine downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $223.01.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229711/shire-plc-shpg-stake-decreased-by-ubs-asset-management-americas-inc.html
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.